While the market fixates on Neuralink's invasive cortical threads, the actual commercialization of brain-computer interfaces is happening at the retinal level. Science Corp's $230 million Series C exposes a critical blind spot in neurotechnology: non-cortical implants are reaching the market years before deep-brain alternatives.
The $1.5 Billion Valuation: Capital Allocation in Neurotechnology
Science Corp closed an oversubscribed $230 million Series C financing round on March 5, 2026, according to corporate filings. This capital injection brings their total funding to $489 million since their 2021 inception. The syndicate includes Lightspeed Venture Partners, Khosla Ventures, Y Combinator, IQT, and Quiet Capital.
This capital injection values the company at $1.5 billion post-money. You are looking at the second most valuable brain-computer interface (BCI) company globally, trailing only Neuralink. Investors are clearly moving away from purely speculative neuroscience to fund immediate, commercializable medical devices.
BCI Sector: Total Capital Raised (Millions USD)
The PRIMA Architecture: Bypassing Degenerated Photoreceptors
The PRIMA system drives this valuation. PRIMA is a 2-millimeter silicon retinal implant designed to restore functional vision to patients suffering from late-stage age-related macular degeneration (AMD). The architecture relies on 378 photovoltaic pixels embedded directly beneath the retina.
Instead of routing cables through the skull, PRIMA uses an external pocket processor and augmented reality glasses. The glasses capture visual data, the processor converts it using AI algorithms, and the glasses project near-infrared light directly onto the retinal implant. The implant then converts this light into electrical signals, stimulating the remaining retinal cells.
The clinical data validates this approach. In the PRIMAvera study, published in the New England Journal of Medicine, researchers implanted the device in 38 blinded patients. **A staggering 84% of these patients achieved clinically meaningful improvements in visual acuity**, regaining the ability to read letters, numbers, and words.
PRIMA System Architecture Flow
Captures visual data
AI signal conversion
Transmits to retina
Stimulates optic nerve
In-House MEMS Manufacturing: Controlling the Silicon Supply Chain
Hardware startups typically die in the supply chain. Science Corp bypassed this bottleneck by acquiring a microelectromechanical systems (MEMS) facility in North Carolina. This acquisition provides complete in-house manufacturing capabilities for their neural interface chips.
When you outsource fabrication, you lose control over iteration speed. By owning the manufacturing floor, Science Corp mitigates third-party delays and reduces unit costs. If you understand the mechanics of custom AI silicon, you know that controlling the physical fabrication layer is the only way to scale hardware profitably.
| Feature Matrix | Science Corp (PRIMA) | Science Corp (Biohybrid) | Neuralink (N1) |
|---|---|---|---|
| Target Area | Sub-retinal (Eye) | Cortical Surface (Brain) | Motor Cortex (Deep Brain) |
| Electrode Count | 378 photovoltaic pixels | 520 surface electrodes | 1,024 penetrating threads |
| Surgical Risk | Low (Outpatient viable) | Medium (Opportunistic placement) | High (Cranial penetration) |
| Primary Indication | Late-stage Macular Degeneration | Stroke / Neural Recording | Quadriplegia / Motor Control |
The Biohybrid Cortical Sensor: A Pragmatic Surgical Approach
Beyond the retina, Science Corp is preparing its next-generation Biohybrid BCI. This device is a pea-sized sensor packed with 520 recording electrodes. Unlike Neuralink's N1 implant, which penetrates brain tissue, the Biohybrid rests on the surface of the cortex.
The surgical strategy here is highly pragmatic. Led by Yale neurosurgery chair Murat Günel, the clinical program will utilize opportunistic placement. Instead of drilling into healthy skulls, surgeons will place the Biohybrid sensor during already-scheduled cranial surgeries, such as those for stroke victims.
**This approach drastically reduces the ethical and surgical barriers to entry for human trials**, which are slated to begin in early 2027. You do not need to recruit healthy patients for highly invasive procedures when you can piggyback on existing craniotomies.
12-to-24 Month Operational Deployment Lifecycle
ROI Calculation: Strategic Financial Impacts
The structural economics of Science Corp's $230 million Series C hinge entirely on their vertical integration strategy. By acquiring a MEMS facility, the company fundamentally alters its capital burn rate.
Consider the standard outsourced BCI manufacturing model. You pay a premium for every prototype run, and you wait months for delivery. The math breaks down as follows:
- Outsourced Iteration Cost: $250,000 per prototype run
- Time Delay: 8-12 weeks per fabrication cycle
- Annual R&D Cycles (Outsourced): 4 cycles = $1,000,000 + 48 weeks lost
By bringing MEMS fabrication in-house, Science Corp restructures this equation entirely:
- In-House Iteration Cost: ~$45,000 (materials + overhead)
- Time Delay: 1-2 weeks per fabrication cycle
- Annual R&D Cycles (In-House): 24 cycles = $1,080,000 + 48 weeks utilized
**Net ROI Impact:** For roughly the same capital expenditure, Science Corp executes 600% more hardware iterations per year. This velocity directly compresses the time-to-market for the PRIMA and Biohybrid systems, accelerating the path to commercial revenue and justifying the $1.5 billion valuation.
Strategic Deployment Risk Vectors
Deploying neural interfaces at scale introduces distinct operational vulnerabilities. We must evaluate the strategic vectors that will determine Science Corp's ability to capture market share over the next 24 months.